Summary.-During studies of the ability of antilymphocyte serum (ALS) to suppress the immune mechanism of mice and thereby allow HeLa cells to grow into a large tumour in the mice, it was observed that many tumours continued to grow even after the ALS treatment had been stopped and full immunological competence of the mice had returned. The HeLa cells of such tumours appeared to be unchanged in their ability to induce further tumours in ALS treated mice to which they were transferred and, furthermore, the mice which were carrying such tumours in the presence of immunological competence were able to reject additional injections of HeLa cells or other human tumour cells. The four possible explanations for this phenomenon, (i) depression of cellular response; (ii) local reaction at the graft site; (iii) the presence of a blocking factor; and (iv) the elevation of the humoral response, have been investigated.
IN 1967 and 1968, Philips and Gazet shQwed that human tumour xenografts grow in mice which had been treated with aritilymphocyte serum (ALS). These results were confirmed by Stanbridge and Perkins (1969) using HeLa cells. In both of these reports, it was shown that the period of active growth of the tumour was short-lived and was eventually followed by regression when the ALS treatment was terminated.
However, in carrying out similar work, we have observed that the growth of tumour cells was maintained for very long periods in a significant number of mice, in spite of the fact that ALS treatment had been terminated. This was surprising, since it has been reported (Medawar, 1969) that mice recover full immunological competence some 50 days after the completion of ALS treatment. If a return had been made to full immunological competence, identical to that existing in untreated mice, then the tumours should have regressed. In the untreated mouse, for example, tumour cells do not grow much beyond 4 days after their inoculation and total rejection occurs by the tenth day. In the present investigations we report tumour survival for many months in mice treated initially with ALS, and have studied the immune state of such tumour bearing mice.
MATERIALS AND METHODS
Antilymphocyte serum was prepared by the method of Medawar (1966a Smears were made of peripheral mouse blood and were examined microscopically for the presence of circulating lymphocytes. Anti-0 serum (Raff, 1969) was conjugated with fluorescein-isothiocyanate, and was then used to demonstrate the presence of thymusdependent (T) lymphocytes in peripheral blood by direct immunofluorescence.
The cytotoxic antibody levels in sera were measured in vitro using a trypan blue dye exclusion test, as follows: confluent HeLa cells less than one week old were trypsinized and then placed in a 5 cm diameter Falcon plastic petri dish which contained two sterile glass cover slips. The petri dish and contents were incubated in CO2 at 37°C for 4 hours, during which time the cells settled on the cover slips. Before use each cover slip was washed in warmed normal saline and the excess saline was removed. To the cells on each coverslip 2A of the serum under test was added together with 2A of absorbed guinea-pig complement (Cohen and Schlesinger, 1970) and this followed by incubation in a moist atmosphere for 30 min at 37°C. It was then washed again and dried. Just sufficient 0.2% trypan blue was added to cover the cells and left to stain for 2 min. The trypan blue was poured off and the cover slip washed in normal saline, dried and mounted on a clean slide in normal saline. The percentage mortality of the HeLa cells on the cover slip was determined by direct count of the percentage of the cells which wete stained.
The sera were examined also for blocking factor after the removal of cytotoxic activity present by absorption in vitro with HeLa cells. The absorbed sera, 0-25 ml, was then injected subcutaneously into normal mice before the inoculation of 2 x 105 HeLa cells in a 0-2 ml inoculum. Control mice received 0-25 ml of normal mouse sera, also treated in vitro with HeLa cells.
The mice were young female adults of the National Institute of Medical Research CBA strain, and the HeLa cells were obtained from the Central Public Health Laboratory. On each occasion, the HeLa cells were cultured in vitro for 4-7 days before inoculation into the mice. (Levey and Medawar, 1 966b) and that allograft rejection is controlled by this cellular response (Mitchison, 1955 (Beverly and Simpson, 1970) .
Our investigations into the presence of a blocking antibody have shown that sera with high cytotoxic titres, measured in vitro, appear to have in vivo blocking activity. Although we have only succeeded in increasing the HeLa cell turmour mean survival rate from 4 to 14 days, when absorbed sera are passively passaged into normal mice before the inoculation of HeLa cells, we feel that the constancy of the observation must be due to some factor in the sera which is not present in normal sera. The detection of a blocking antibody reinforces the hypothesis that enhancement may be an additional factor contributing to long-term tumour survival, though in view of this limited extensiln of graft growth using passive serum transfer, its significance is equivocal. Enhancement has been demonstrated many times for allogeneic tumours (Takasugi and Hildemann, 1969a, b) and recently for syngeneic tumours (Hellstrom and Hellstrom, 1970) .
The observations reported here do not support the hypothesis that immunological tolerance is a satisfactory explanation for this phenomenon. They fail also to support the hypothesis that long-term survival of tumours is a function of a change in surface antigenicity during growth in vivo. Passaged tumours were rejected in untreated mice though the mean time for rejection was increased. This was probably due to the greater size of the passaged HeLa cell implant over and above that given by an initial inoculation of cell suspension.
The tumours that survive are well localized at the site of inoculation, have a good blood supply and are coated with a hypofibrous layer. There is a complete absence of macroscopic and microscopic metastases and the host mice have been shown to reject another human tumorigenic cell line and, furthermore, they rapidly destroy additional inoculations of the original HeLa cells even though they continue to maintain the original HeLa cell tumour. This phenomenon of concomitant immunity has been observed by many investigators in the field of tumour transplantation (Ehrlich, 1906; 1908; Gershon, Carter and Kondo Kazunari, 1967; Carter, 1970) , and may be explained by the fact that tumour survival is a result of a local reaction at the graft site.
Wre feel that long-term tumour survival is not yet fully understood and there may be more than one controlling factor involved. In our investigations we have referred to four possibilities: depression of the cellular response, a local reaction at the graft site, the effect of blocking factor and the elevation of the humoral response. It is suggested that only when these are acting in the same direction tumour survival occurs. It is not surprising therefore that there is a 33%0 failure rate.
